Dyslipidemia Disease Analysis and Market and Forecast Analysis 2024

Disease Overview
Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated LDL-C due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular disease, one of the world’s leading causes of morbidity and mortality. Other lipid level deviations in dyslipidemia include low levels of HDL-C, elevated total cholesterol, and elevated triglycerides.

Market Snapshot

• Generic erosion of key legacy product sales will be offset by the growth of the branded PCSK9 inhibitor class.


• The author’s primary research survey of 238 physicians sheds light on prescribing patterns in dyslipidemia.


• Dyslipidemia is a serious public health concern, as prevalence is high and it is a strong risk factor for CVD and CAD.


• Positive CVOT data combined with steep discounts will drive PCSK9 uptake.


• Inclisiran is a promising pipeline medication and has the opportunity to provide cost-effective PCSK9 inhibition.


• Payers impose strict access controls on PCSK9 inhibitors.